Genmab — Januar 2020
-
-
God morgen.
-
God morgen
-
-
Ola Landgren, M.D.
@DrOlaLandgren
·
6 t
Svarer
@BrizzleDoc
og
@VJHemOnc
We showed at ASH 2019: (1) No additional grade >3 toxicities with weekly KRd-daratumumab (vs standard of care KRd); (2) No grade >3 peripheral neuropathy; (3) No deaths on study; (4) Total 30 dose reductions in 21 pts; majority were lenalidomide (N=15) and dexamethasone (N=12)https://twitter.com/DrOlaLandgren/status/1223056579077070849 -
News: GENMAB A/S <GMAB.CO>: GUGGENHEIM CUTS PRICE TARGET TO DKK 1760 FROM DKK 1804 - RTRS | News Wires | Thomson Reuters Eikon
-
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis https://link.springer.com/article/10.1007%2Fs40263-020-00704-w full pdf
https://sci-hub.tw/https://link.springer.com/article/10.1007%2Fs40263-020-00704-w -
-
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study https://www.nature.com/articles/s41375-020-0711-6
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind